Suppliers / Bayer De Mexico, S.A. De C.V

Bayer De Mexico, S.A. De C.V

Mexico Updated 9 July 2026

Bayer De Mexico, S.A. De C.V is a finished-dose manufacturer based in Mexico. It appears in 34 regulatory filings across 3 regulators, without an active US DMF or CEP on file. Its filings concentrate with COFEPRIS (MX), MINSA (CR) and INVIMA (CO). Its GMP standing is certified by COFEPRIS (MX), ANVISA (Brazil) and EMA. Its most recent recorded inspection, by US FDA, closed on 9 December 2022 as VAI. Customs aggregates show $2.0M of exports covering 9 molecules to 4 destinations in 2024.

0
active US DMFs
0
valid CEPs
8
registered plants 2 with an FDA FEI number
34
filings across 3 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
6 of 6 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 9 December 2022 VAI US FDA
  • 25 January 2019 VAI US FDA
  • 11 May 2018 VAI US FDA
  • 23 October 2015 VAI US FDA
  • 14 February 2014 NAI US FDA
  • 5 November 2010 NAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Lerma, Colombia Not on file
LERMA, Mexico Not on file
Ixtaczoquitlán, Mexico Not on file
Mexico, Mexico 3002807925
Mexico, Mexico 3002806479
Lerma, Mexico Not on file

2 further sites are on record.

Filings and GMP by regulator

Regulator Filings GMP certificates
COFEPRIS (MX) 18 8
MINSA (CR) 9 None
INVIMA (CO) 7 None
ANVISA (Brazil) None 3
EMA None 2

Scale

Year Revenue Exports Destinations
2024 Not reported $2.0M 4
2023 Not reported $119.1M 18
2022 Not reported $96.9M 20

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Bayer De Mexico, S.A. De C.V comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 9 December 2022.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts